ATE398180T1 - Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna - Google Patents
Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrnaInfo
- Publication number
- ATE398180T1 ATE398180T1 AT02731102T AT02731102T ATE398180T1 AT E398180 T1 ATE398180 T1 AT E398180T1 AT 02731102 T AT02731102 T AT 02731102T AT 02731102 T AT02731102 T AT 02731102T AT E398180 T1 ATE398180 T1 AT E398180T1
- Authority
- AT
- Austria
- Prior art keywords
- apolipoprotein
- methods
- apobec
- modifying
- mrna
- Prior art date
Links
- 101710095342 Apolipoprotein B Proteins 0.000 title abstract 4
- 102100040202 Apolipoprotein B-100 Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 abstract 3
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000000923 atherogenic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 230000017156 mRNA modification Effects 0.000 abstract 1
- 239000002353 niosome Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27185601P | 2001-02-27 | 2001-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE398180T1 true ATE398180T1 (de) | 2008-07-15 |
Family
ID=23037380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02731102T ATE398180T1 (de) | 2001-02-27 | 2002-02-26 | Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040115184A1 (de) |
| EP (1) | EP1392846B1 (de) |
| JP (1) | JP2004521625A (de) |
| AT (1) | ATE398180T1 (de) |
| CA (1) | CA2439472A1 (de) |
| DE (1) | DE60227069D1 (de) |
| WO (1) | WO2002068676A2 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004013160A2 (en) * | 2002-08-05 | 2004-02-12 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
| WO2005023985A2 (en) * | 2003-09-03 | 2005-03-17 | University Of Rochester | Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof |
| US8158770B2 (en) | 2004-05-06 | 2012-04-17 | University Of Rochester | Content dependent inhibitors of cytidine deaminases and uses thereof |
| EP2059122B1 (de) * | 2006-08-28 | 2012-06-20 | University of Rochester | Verfahren und zusammensetzungen in verbindung mit der expression von apobec-1 |
| WO2010039223A2 (en) | 2008-09-30 | 2010-04-08 | The Regents Of The University Of California | T-cell immunogens derived from anti-viral proteins and methods of using same |
| EP2731964A2 (de) * | 2011-07-12 | 2014-05-21 | Regents of the University of Minnesota | Mikroutrophin-polypeptide und verfahren |
| EP3613852A3 (de) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Beurteilung und verbesserung einer nukleasespaltungsspezifität |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| GB2568182A (en) | 2016-08-03 | 2019-05-08 | Harvard College | Adenosine nucleobase editors and uses thereof |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| GB2573062A (en) | 2016-10-14 | 2019-10-23 | Harvard College | AAV delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物 |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| EP3799603A4 (de) | 2018-05-11 | 2022-03-02 | Beam Therapeutics, Inc. | Verfahren zur substitution von pathogenen aminosäuren unter verwendung von programmierbaren baseneditorsystemen |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12454694B2 (en) | 2018-09-07 | 2025-10-28 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| AU2020240109A1 (en) | 2019-03-19 | 2021-09-30 | President And Fellows Of Harvard College | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2021056302A1 (en) * | 2019-09-26 | 2021-04-01 | Syngenta Crop Protection Ag | Methods and compositions for dna base editing |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| BR112022022603A2 (pt) | 2020-05-08 | 2023-01-17 | Broad Inst Inc | Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla |
| CA3219767A1 (en) * | 2021-05-14 | 2022-11-17 | Beam Therapeutics Inc. | Compositions and methods for treating transthyretin amyloidosis |
| CN113234745B (zh) * | 2021-06-11 | 2021-11-02 | 山东祥维斯生物科技股份有限公司 | 利用PTD-Tat实现海洋微生物低温脂肪酶基因的跨膜转导方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468022A (en) * | 1994-06-14 | 1995-11-21 | Massachusetts Institute Of Technology | Sample tube identification flag |
| US6041253A (en) * | 1995-12-18 | 2000-03-21 | Massachusetts Institute Of Technology | Effect of electric field and ultrasound for transdermal drug delivery |
| US5866333A (en) * | 1996-03-01 | 1999-02-02 | Regents Of The University Of California | Screening methods to detect mRNA targets of editing enzymes |
| US5747319A (en) * | 1996-07-25 | 1998-05-05 | Incyte Pharmaceuticals, Inc. | Human mRNA editing enzyme |
| US6130200A (en) * | 1996-12-20 | 2000-10-10 | Alza Corporation | Gel composition and methods |
| US5804185A (en) * | 1997-03-13 | 1998-09-08 | Incyte Pharmaceuticals, Inc. | RNA editing enzyme REE-2 |
| FR2773079B1 (fr) * | 1997-12-30 | 2002-05-17 | Itzik Harosh | Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii |
| CA2442909C (en) * | 2001-04-06 | 2011-11-29 | Thomas Jefferson University | Multimerization of hiv-1 vif protein as a therapeutic target |
| US20040009951A1 (en) * | 2002-06-13 | 2004-01-15 | Malim Michael H | DNA deamination mediates innate immunity to (retro)viral infection |
| WO2004013160A2 (en) * | 2002-08-05 | 2004-02-12 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
| US7220554B2 (en) * | 2003-05-23 | 2007-05-22 | Oregon Health And Science University | Methods for identifying inhibitors |
| WO2005023985A2 (en) * | 2003-09-03 | 2005-03-17 | University Of Rochester | Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof |
-
2002
- 2002-02-26 DE DE60227069T patent/DE60227069D1/de not_active Expired - Lifetime
- 2002-02-26 JP JP2002568770A patent/JP2004521625A/ja not_active Withdrawn
- 2002-02-26 EP EP02731102A patent/EP1392846B1/de not_active Expired - Lifetime
- 2002-02-26 CA CA002439472A patent/CA2439472A1/en not_active Abandoned
- 2002-02-26 AT AT02731102T patent/ATE398180T1/de not_active IP Right Cessation
- 2002-02-26 US US10/468,987 patent/US20040115184A1/en not_active Abandoned
- 2002-02-26 WO PCT/US2002/005824 patent/WO2002068676A2/en not_active Ceased
-
2010
- 2010-05-20 US US12/784,310 patent/US20100297219A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002068676A3 (en) | 2003-12-24 |
| JP2004521625A (ja) | 2004-07-22 |
| DE60227069D1 (de) | 2008-07-24 |
| EP1392846B1 (de) | 2008-06-11 |
| WO2002068676A2 (en) | 2002-09-06 |
| EP1392846A2 (de) | 2004-03-03 |
| CA2439472A1 (en) | 2002-09-06 |
| EP1392846A4 (de) | 2005-09-21 |
| US20040115184A1 (en) | 2004-06-17 |
| US20100297219A1 (en) | 2010-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE398180T1 (de) | Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna | |
| AU4185001A (en) | Protein scaffolds for antibody mimics and other binding proteins | |
| ATE277198T1 (de) | Verfahren zur in vitro evolution von proteinfunktionen | |
| ATE439592T1 (de) | Proteingerüste für antikörper-nachahmer und andere bindende proteine | |
| WO2004101740A3 (en) | Clotting factor-fc chimeric proteins to treat hemophilia | |
| DK0770139T3 (da) | En svamp, hvor areA-genet er blevet modificeret, samt et areA-gen fra aspergillus oryzae | |
| DE69917716D1 (de) | Protein-deamiderendes Enzym, dafür kodierendes Gen, Verfahren zur Herstellung und Verwendung davon | |
| ATE511833T1 (de) | Nanopartikel aus protein mit gekoppeltem apolipoprotein e zur überwindung der blut-hirn- schranke und verfahren zu ihrer herstellung | |
| ATE373719T1 (de) | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung | |
| ATE368095T1 (de) | Verfahren zur herstellung von mitteldistillaten | |
| ATE352617T1 (de) | Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper | |
| DE69723074D1 (de) | Mch4 und mch5, apoptotische proteasen, dafür kodierende nukleinsäure und verfahren zur verwendung | |
| DE69931946D1 (de) | Zusammensetzungen und verfahren zur zubereitung von dispersionen und verfahren zur verwendung der dispersionen | |
| ATE135371T1 (de) | Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis | |
| DE60230456D1 (de) | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren | |
| ATE309353T1 (de) | Verfahren zur herstellung von rekombinanten peptiden | |
| DE69513027D1 (de) | Verfahren zur bestimmung des präthrombotischen status | |
| DE69835813D1 (de) | Verfahren zur kultivierung von zellen und zur vermehrung von viren | |
| ATE506370T1 (de) | Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen | |
| ATE230414T1 (de) | Mimetika von beta-faltblatt und verfahren zur verwendung davon | |
| WO2003068940A3 (en) | Complexes and methods of using same | |
| Verhoeven et al. | Hepatic lipase mRNA is expressed in rat and human steroidogenic organs | |
| ATE417112T1 (de) | Steigerung der immunantwort unter verwendung von zielgerichteten molekülen | |
| DE60239450D1 (de) | Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten | |
| ATE541584T1 (de) | Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |